Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CRIS
CRIS logo

CRIS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Curis Inc (CRIS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.340
1 Day change
66.57%
52 Week Range
2.730
Analysis Updated At
2026/06/26
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Curis Inc (CRIS) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading in a clear downtrend, there is no supportive news flow or catalyst, no bullish proprietary trading signal, and the broader sentiment from hedge funds and insiders is neutral. Even though the RSI is deeply oversold, the overall technical structure remains weak, so this is not a strong entry for someone who wants a direct buy now.

Technical Analysis

CRIS is technically bearish. The MACD histogram is below zero and still expanding negatively, showing downside momentum remains intact. RSI_6 is 9.901, which signals heavily oversold conditions, but oversold alone does not confirm a reversal. The moving averages are stacked bearishly with SMA_200 > SMA_20 > SMA_5, confirming a strong downtrend. Price at 0.2079 is below the pivot level of 0.367 and near S1 support at 0.23, with deeper downside risk toward S2 at 0.145 if support fails. The short-term pattern analysis also projects weak forward returns over the next week and month.

Positive Catalysts

  • The only mildly positive factor is the deeply oversold RSI, which could allow for a technical bounce. The stock also showed a small pre-market move of 5.50% and a slight post-market uptick of 1.02%, but these are not enough to outweigh the broader bearish setup.

Neutral/Negative Catalysts

  • There is no recent news in the past week, so no event-driven catalyst is visible. Hedge fund and insider trading trends are both neutral, with no meaningful accumulation signal. The stock suffered a large regular session decline of 39.51%, the technical trend is bearish across multiple indicators, and no AI Stock Picker or SwingMax signal is present. Congress trading data is also absent, so there is no influential buying support.

Financial Performance

No usable latest-quarter financial snapshot was provided because the financial data returned an error, so the latest quarter season cannot be assessed from the available data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided. Based on the available information, Wall Street appears neutral to weakly negative by default, since there is no visible analyst support, no recent upgrades, no positive target revisions, and no catalyst-driven bullish consensus.

Wall Street analysts forecast CRIS stock price to rise
2 Analyst Rating
Wall Street analysts forecast CRIS stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.206
sliders
Low
5
Averages
11
High
17
Current: 0.206
sliders
Low
5
Averages
11
High
17
Evercore ISI
Outperform
downgrade
$40 -> $38
AI Analysis
2026-01-05
Reason
Evercore ISI
Price Target
$40 -> $38
AI Analysis
2026-01-05
downgrade
Outperform
Reason
Evercore ISI lowered the firm's price target on Caris Life Sciences to $38 from $40 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.
Canaccord
Kyle Mikson
Hold
maintain
$28 -> $30
2025-12-22
Reason
Canaccord
Kyle Mikson
Price Target
$28 -> $30
2025-12-22
maintain
Hold
Reason
Canaccord analyst Kyle Mikson raised the firm's price target on Caris Life Sciences to $30 from $28 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. They beleve Caris Life Sciences could be attractive with continued momentum or a material share price pullback.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CRIS
Unlock Now

People Also Watch